Singapore: Kaneka launched KanCapA, a new protein A chromatography resin for the purification of therapeutic antibodies. KANEKA KanCapA exhibits high antibody adsorbing capacity and alkaline resistance.

Therapeutic antibodies represent an innovative class of drugs used to treat a wide range of diseases such as rheumatoid arthritis and cancer. Protein A chromatography resin is widely used in the production of therapeutic antibodies due to its high affinity and excellent selectivity for antibodies.

Utilizing its expertise in protein design and genetic engineering, the company has made significant improvements to 'wild type' or 'native' protein A ligand. Immobilization of the improved protein A ligand to highly cross-linked cellulose beads allows KANEKA KanCapA to exhibit alkaline resistance, stability over repeated cycle use, and to be used at high flow rates from laboratory to industrial scale with high binding capacity.

As a result of positive feedback and evaluation results from the customers the company announced the commercialization and sales of KANEKA KanCapA in October 2012. The company will introduce KANEKA KanCapA at BioProcess International (October 8-12, US) and at CPhI Worldwide (October 9-11, Spain). The expectation is that the excellent properties of KANEKA KanCapA will allow customers to develop stable, streamlined and cost effective antibody purification processes.

In addition the company is investing our research and technology resources towards the development of the next generation chromatography resins having the high quality and novel performance for the production of biopharmaceuticals. Along with the group companies, Eurogentec for contract manufacturing of biopharmaceuticals and GeneFrontier Corporation (Chiba, Japan) for drug candidate exploration, KANEKA will continue to offer technical and cost effective solutions in the field of biopharmaceuticals